

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**





## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification</b> <sup>7</sup> : <b>A61K 31/197, A61P 13/10</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 00/61135</b> <b>(43) International Publication Date:</b> 19 October 2000 (19.10.00)
<b>(21) International Application Number:</b> PCT/US00/02141 <b>(22) International Filing Date:</b> 27 January 2000 (27.01.00) <b>(30) Priority Data:</b> 60/128,347 8 April 1999 (08.04.99) US <b>(71) Applicant (for all designated States except US):</b> WARNER-LAMBERT COMPANY [US/US]; 201 Tabor Road, Morris Plains, NJ 07950 (US). <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> SEGAL, Catherine, A. [US/US]; 5 Dogwood Drive, Chester, NJ 07930 (US). MAGNUS, Leslie [US/US]; 68 Rockledge Drive, Liv- ingston, NJ 07039 (US). <b>(74) Agents:</b> RYAN, Andrea, M. et al.; Warner-Lambert Company, 201 Tabor Road, Morris Plains, NJ 07950 (US).		<b>(81) Designated States:</b> AE, AL, AU, BA, BB, BG, BR, CA, CN, CR, CU, CZ, DM, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZA, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i>
<b>(54) Title:</b> METHOD FOR THE TREATMENT OF INCONTINENCE  <b>(57) Abstract</b>  The instant invention is a method of using certain analogs of glutamic acid and gamma-aminobutyric acid to treat incontinence.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

## METHOD FOR THE TREATMENT OF INCONTINENCE

## BACKGROUND OF THE INVENTION

1. Field Of The Invention

5 The present invention relates to the use of analogs of glutamic acid and gamma-aminobutyric acid (GABA) for the treatment of incontinence.

2. Description of Related Art

10 GABA analogs are known agents useful in antiseizure therapy for central nervous system disorders such as epilepsy, Huntington's chorea, cerebral ischemia, Parkinson's disease, tardive dyskinesia, and spasticity. It has also been suggested that the compounds can be used as antidepressants, anxiolytics, and antipsychotics. See WO 92/09560 (United States Serial Number 618,692 filed November 27, 1990) and WP 93/23383 (United States Serial Number 886,080 filed May 20, 1992).

15 WO 97/33858 teaches that compounds related to gabapentin are useful or treating epilepsy, faintness attacks, hypokinesia, cranial disorders, neurodegenerative disorders, depression, anxiety, panic, pain, and neuropathological disorders. WO 97/33858 does not specify what forms of pain  
20 are treated.

Additionally, the compounds of the invention are known for treatment of

- neuropathic pain. For example, see Rosner H; Rubin L; Kestenbaum A., Gabapentin adjunctive therapy in neuropathic pain states. Clin J Pain, 1996 Mar, 12:1, 56-8; Segal AZ; Rordorf G., Gabapentin as a novel treatment for postherpetic neuralgia. Neurology, 1996 Apr, 46:4, 1175-6; Wetzel CH; Connelly JF., Use of gabapentin in pain management. Ann Pharmacother, 1997 Sep, 31:9, 1082-3; Zapp JJ., Postpoliomyelitis pain treated with gabapentin [letter]. Am Fam Physician, 1996 Jun, 53:8, 2442, 2445; Cheville A, et al., Neuropathic pain in radiation myelopathy: a case report. Program book, American Pain Society (14th Annual Scientific Meeting). Abstract #95823, p. A-115; Sist T; Filadora V; Miner M; Lema M., Gabapentin for idiopathic trigeminal neuralgia: report of two cases. Neurology, 1997 May, 48:5, 1467; Waldman SD, Tutorial 28: Evaluation and Treatment of Trigeminal Neuralgia. Pain Digest (1997) 7:21-24; Mellick LB; Mellick GA., Successful treatment of reflex sympathetic dystrophy with gabapentin [letter]. Am J Emerg Med, 1995 Jan, 13:1, 96; Mellick GA; Seng MI., The use of gabapentin in the treatment of reflex sympathetic dystrophy and a phobic disorder. Am J Pain Manage 1995; 5:7-9; Mellick GA; Mellicy LB; Mellick LB., Gabapentin in the management of reflex sympathetic dystrophy [letter]. J Pain Symptom Manage, 1995 May, 10:4, 265-6; Mellick GA; Mellick LB., Reflex sympathetic dystrophy treated with gabapentin. Arch Phys Med Rehabil, 1997 Jan, 78:1, 98-105 and Mackin GA., Medical and pharmacologic management of upper extremity neuropathic pain syndromes. J Hand Ther, 1997 Apr-Jun, 10:2, 96-109.

Urinary incontinence (UI) is often described as either urge incontinence, where urine lost is associated with a sudden or strong desire to void, or stress


incontinence, where urine loss is associated with coughing, laughing, or physical exercise. A more general category, mixed incontinence, includes those patients showing both stress and urge symptoms.

5        Although urinary incontinence is quite prevalent, it is still under-diagnosed and under-reported. The U.S. Department of Health and Human Services estimates that UI affects over 13 million Americans at a cost in excess of \$15 billion per year. Many victims of UI do not seek help because of embarrassment or a perception that nothing can be done about their problem. Consequently, the  
10        general health and social life of these victims may be significantly compromised for years.

### SUMMARY OF THE INVENTION

The invention related to methods for treating patients having urinary incontinence. In methods according to the invention, compositions comprising a  
15        gaba analog in a pharmaceutically-acceptable vehicle are administered to a patient suffering from urinary incontinence.


This invention provides a method for treating incontinence in a mammal comprising administering to a subject suffering from incontinence an effective  
20        amount of a GABA analog. A preferred embodiment utilizes a cyclic amino acid compound of Formula I



wherein  $\text{R}_1$  is hydrogen or lower alkyl and  $n$  is an integer of from 4 to 6, and the pharmaceutically acceptable salts thereof. An especially preferred embodiment utilizes a compound of Formula I where  $\text{R}_1$  is hydrogen and  $n$  is 4, which compound is 1-(aminomethyl)-cyclohexane acetic acid, known generically as gabapentin.

In another embodiment, the invention includes treating incontinence with a compound of Formula II.

Formula II



II

or a pharmaceutically acceptable salt thereof wherein

$\text{R}_1$  is a straight or branched alkyl of from 1 to 6 carbon atoms, phenyl, or cycloalkyl of from 3 to 6 carbon atoms;

$\text{R}_2$  is hydrogen or methyl; and

$\text{R}_3$  is hydrogen, methyl, or carboxyl.



Preferred compounds of the invention are those wherein  $R_3$  and  $R_2$  are hydrogen, and  $R_1$  is  $-(CH_2)_{0-2}-i C_4H_9$  as an (R), (S), or (R,S) isomer.

The more preferred compounds of Formula II invention are (S)-3-(aminomethyl)-5-methylhexanoic acid and 3-aminomethyl-5-methyl-hexanoic acid, now known generically as pregabalin.

#### DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

The method of this invention utilizes any GABA analog. A GABA analog is any compound derived from or based upon gamma-aminobutyric acid. The compounds are readily available, either commercially, or by synthetic methodology well-known to those skilled in the art of organic chemistry. The preferred GABA analogs to be utilized in the method of this invention are cyclic amino acids of Formula I. These are described in U.S. Patent 4,024,175, which is incorporated herein by reference. Another preferred method utilizes the GABA analogs of Formula II, and these are described in U.S. Patent 5,563,175 which is incorporated herein by reference.

All that is required to practice the method of this invention is to administer a GABA analog in an amount that is effective to treat incontinence. Such amounts will generally be from about 1 to about 300 mg per kg of subject body weight. Typical doses will be from about 10 to about 5000 mg per day for an adult subject of normal weight. It is expected that common doses that might be administered could be from 100 mg three times a day up to 600 mg four times a

day. Commercially available capsules of 100 mg, 300 mg, and 400 mg of gabapentin can be administered. Alternate forms include liquids and film-coated tablets.

5        If a compound of Formula II, such as pregabalin is used, the dosage level is one sixth that of gabapentin. The dosage range for pregabalin is from about 0.15 mg to about 50 mg per kg per day of subject body weight. Typical dosages for pregabalin will be from about 1.6 mg to about 840 mg per day with individual dosages ranging from about 0.15 mg to about 65 mg per dose.

10        While not wishing to be bound by any theory, the inventors believe that the gaba analogs work to control incontinence in the following manner. Incontinence is not associated with pain. A person can sense a full bladder. In overflow incontinence, such as which occurs after a stroke, the feedback loop  
15        from the bladder to the brain is broken and the bladder fills and fills until it overflows. This mechanism would be different for urge and stress incontinence. Applicants believe that over sensitivity and irritability of the nerve endings on the bladder sphincter escalate to the point of urge incontinence. Therefore a product that stabilizes and reduces the sensitivity of these nerve fibers breaks the cycle  
20        that leads to failure of the muscular control of the sphincter.

      The compounds used in the present invention may form pharmaceutically acceptable salts with both organic and inorganic acids or bases. For example, the acid addition salts of the basic compounds are prepared either by dissolving the  
25        free base in aqueous or aqueous alcohol solution or other suitable solvents

containing the appropriate acid and isolating the salt by evaporating the solution. Examples of pharmaceutically acceptable salts are hydrochlorides, hydrobromides, hydrosulfates, etc. as well as sodium, potassium, and magnesium, etc. salts.

5

The compounds of the Formula II can contain one or several asymmetric carbon atoms. The invention includes the individual diastereomers or enantiomers, and the mixtures thereof. The individual diastereomers or enantiomers may be prepared or isolated by methods already well-known in the art.

10

Pharmaceutical compositions of the compound of the present invention or its salts are produced by formulating the active compound in dosage unit form with a pharmaceutical carrier. Some examples of dosage unit forms are tablets, capsules, pills, powders, aqueous and nonaqueous oral solutions and suspensions, and parenteral solutions packaged in containers containing either one or some larger number of dosage units and capable of being subdivided into individual doses.

15

20

Some examples of suitable pharmaceutical carriers, including pharmaceutical diluents, are gelatin capsules; sugars such as lactose and sucrose; starches such as corn starch and potato starch, cellulose derivatives such as sodium carboxymethyl cellulose, ethyl cellulose, methyl cellulose, and cellulose acetate phthalate; gelatin; talc; stearic acid; magnesium stearate; vegetable oils such as peanut oil, cottonseed oil, sesame oil, olive oil, corn oil, and oil of theobroma; propylene glycol, glycerin; sorbitol; polyethylene glycol; water; agar;

25

alginic acid; isotonic saline, and phosphate buffer solutions; as well as other compatible substances normally used in pharmaceutical formulations. The compositions of the invention can also contain other components such as coloring agents, flavoring agents, and/or preservatives. These materials, if present, are usually used in relatively small amounts. The compositions can, if desired, also contain other therapeutic agents.

The percentage of the active ingredients in the foregoing compositions can be varied within wide limits, but for practical purposes it is preferably present in a concentration of at least 10% in a solid composition and at least 2% in a primary liquid composition. The most satisfactory compositions are those in which a much higher proportion of the active ingredient is present.


Routes of administration of the subject compound or its salts are oral or parenteral. For example, a useful intravenous dose is between 5 and 50 mg and a useful oral dosage is between 20 and 800 mg. The dosage is within the dosing range used in treatment of pain or as would be with the needs of the patient as described by the physician.

While the invention has been described in detail and with reference to specific examples thereof, it will be apparent to one skilled in the art that various changes and modifications can be made therein without departing from the spirit and scope thereof.

What is claimed is:

1. A method for treating a mammal suffering from incontinence comprising administering to said mammal a pharmaceutical composition comprising a GABA analog in an amount sufficient to alleviate symptoms of urinary incontinence.

2. The method according to claim 1, wherein the GABA analog is the compound according to Formula I:



I


wherein  $\text{R}_1$  is hydrogen or lower alkyl and  $n$  is an integer of from 4 to 6, and the pharmaceutically acceptable salts thereof.

3. The method according to claim 2, wherein Formula I comprises gabapentin.

4. The method according to claim 2, comprising from about 10 mg to about 400 mg of Formula I.

5. The method according to claim 3, comprising from about 10 mg to about 400 mg of gabapentin.

6. The method according to claim 1, wherein the GABA analog is a compound according to Formula II:



or a pharmaceutically acceptable salt thereof wherein

$R_1$  is a straight or branched alkyl of from 1 to 6 carbon atoms, phenyl, or

10 cycloalkyl of from 3 to 6 carbon atoms;

$R_2$  is hydrogen or methyl; and

$R_3$  is hydrogen, methyl, or carboxyl;

7. The method according to claim 11, wherein Formula II comprises pregabalin.

15 8. The method according to claim 11, comprising from about .15 mg to about 65 mg of Formula II.

9. The method according to claim 12, comprising from about .15 mg to about 65 mg of pregabalin.

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/02141

**A. CLASSIFICATION OF SUBJECT MATTER**  
IPC 7 A61K31/197 A61P13/10

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)  
IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	GIL-NAGEL A. ET AL: "Incontinence during treatment with gabapentin" NEUROLOGY, MAY 1997, 48 (5) P1467-8, XP000910004 UNITED STATES * p.1468, 1st col., Discussion, par. bridging 1st and 2nd col; 2nd col., 1st.-2nd par *	1-5
X	DOHERTY ET AL: "Gabapentin in a medically refractory epilepsy population: Seizure response and unusual side effects." EPILEPSIA, , vol. 36, no. 4, 1995, page 71 XP002139721 no. 3-54 abstract  -/--	1-5

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

\* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

8 June 2000

Date of mailing of the international search report

29/06/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Uiber, P

## INTERNATIONAL SEARCH REPORT

Int. :ional Application No

PCT/US 00/02141

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	IGAWA Y. ET AL: "Effects of GABA-receptor stimulation and blockade on micturition in normal rats and rats with bladder outflow obstruction." JOURNAL OF UROLOGY, AUG 1993, 150 (2 PT 1) P537-42, XP000909994 UNITED STATES abstract	1
Y	the whole document	2-9
X	WO 98 09948 A (NICOX SA ;DEL SOLDATO PIERO (IT); SANNICOLA FRANCESCO (IT)) 12 March 1998 (1998-03-12) page 2, paragraph 2	1
Y	page 5, paragraph 2	2-9
X	MAGGI CA ET AL: "Neuroeffector mechanisms in the voiding cycle of the guinea-pig urinary bladder." JOURNAL OF AUTONOMIC PHARMACOLOGY, DEC 1987, 7 (4) P295-308, XP000909967 ENGLAND abstract	1
Y	page 306 -page 307	2-9
Y	WO 92 09560 A (UNIV NORTHWESTERN) 11 June 1992 (1992-06-11) cited in the application claims 1-16	6-9
E	WO 00 12692 A (BOROWSKY BETH ;JONES KENNETH A (US); LAZ THOMAS M (US); SYNAPTIC P) 9 March 2000 (2000-03-09) claim 175	1



# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 00/02141

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9809948 A	12-03-1998	IT MI961821 A	04-03-1998
		AU 4301097 A	26-03-1998
		CN 1234792 A	10-11-1999
		EP 0931065 A	28-07-1999
WO 9209560 A	11-06-1992	AU 9137091 A	25-06-1992
		MX 9102241 A	31-01-1994
		US 6028214 A	22-02-2000
		US 5563175 A	08-10-1996
		US 5684189 A	04-11-1997
		US 5608090 A	04-03-1997
		US 5599973 A	04-02-1997
		US 5710304 A	20-01-1998
		US 5847151 A	08-12-1998
WO 0012692 A	09-03-2000	NONE	

**THIS PAGE BLANK (USPTO)**